Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, an Innovative Long-Acting Anti-TSLP Antibody Designed to Treat Severe Asthma#USA#Somerville#GB-0895#Generate_Biomedicines#asthma
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, an Innovative Long-Acting Anti-TSLP Antibody Designed to Treat Severe Asthma
Generate Biomedicines has announced the initiation of global Phase 3 clinical trials for GB-0895, an innovative long-acting antibody aimed at severe asthma treatment.
third-news.com
December 1, 2025 at 4:32 PM
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, an Innovative Long-Acting Anti-TSLP Antibody Designed to Treat Severe Asthma#USA#Somerville#GB-0895#Generate_Biomedicines#asthma
Generate Biomedicines Launches Global Phase III Trials for Antibody GB-0895 in Severe Asthma Treatment#USA#Somerville#GenerateBiomedicines#GB-0895#TSLP
Generate Biomedicines Launches Global Phase III Trials for Antibody GB-0895 in Severe Asthma Treatment
Generate Biomedicines has announced the initiation of global Phase III clinical trials for GB-0895, a long-acting antibody developed using AI for treating severe asthma. The trials aim to evaluate its effectiveness in about 1600 patients.
third-news.com
December 1, 2025 at 3:58 PM
Generate Biomedicines Launches Global Phase III Trials for Antibody GB-0895 in Severe Asthma Treatment#USA#Somerville#GenerateBiomedicines#GB-0895#TSLP
Generate:Biomedicines Memulai Penelitian Fase 3 Global Tentang GB-0895, Antibodi Anti-TSLP yang Direkayasa AI Untuk Asma Berat - https://www.antaranews.com/berita/5280113/generatebiomedicines-memulai-penelitian-fase-3-global-tentang-gb-0895-antibodi-anti-tslp-yang-direkayasa-ai-untuk-asma-berat
Generate:Biomedicines Memulai Penelitian Fase 3 Global Tentang GB-0895, Antibodi Anti-TSLP yang Direkayasa AI Untuk Asma Berat
Hari ini Generate:Biomedicines ("Generate")mengumumkan rencana memulai dua uji klinis Fase 3 global, yakni SOLAIRIA-1 dan SOLAIRIA-2, untuk ...
www.antaranews.com
December 1, 2025 at 12:29 PM
Generate:Biomedicines Memulai Penelitian Fase 3 Global Tentang GB-0895, Antibodi Anti-TSLP yang Direkayasa AI Untuk Asma Berat - https://www.antaranews.com/berita/5280113/generatebiomedicines-memulai-penelitian-fase-3-global-tentang-gb-0895-antibodi-anti-tslp-yang-direkayasa-ai-untuk-asma-berat
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, Addressing Severe Asthma with AI Innovation#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, Addressing Severe Asthma with AI Innovation
Generate Biomedicines has announced two global Phase 3 clinical trials for GB-0895, a long-acting anti-TSLP antibody designed for severe asthma treatment, engineered with AI technology.
third-news.com
December 1, 2025 at 11:20 AM
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895, Addressing Severe Asthma with AI Innovation#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
GenerateBiomedicines Launches Phase 3 Trials of GB-0895 for Severe Asthma#USA#Somerville#GenerateBiomedicines#GB-0895#SOLAIRIA
GenerateBiomedicines Launches Phase 3 Trials of GB-0895 for Severe Asthma
GenerateBiomedicines embarks on pivotal Phase 3 trials for GB-0895, an advanced treatment for severe asthma, showcasing the potential of AI-driven drug design.
third-news.com
December 1, 2025 at 11:20 AM
GenerateBiomedicines Launches Phase 3 Trials of GB-0895 for Severe Asthma#USA#Somerville#GenerateBiomedicines#GB-0895#SOLAIRIA
GenerateBiomedicines Launches Global Phase-3 Studies for GB-0895, an AI-Engineered Antibody Targeting Severe Asthma#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
GenerateBiomedicines Launches Global Phase-3 Studies for GB-0895, an AI-Engineered Antibody Targeting Severe Asthma
Explore the groundbreaking Phase-3 trials initiated by GenerateBiomedicines for GB-0895, an AI-designed antibody aimed at treating severe asthma.
third-news.com
December 1, 2025 at 11:19 AM
GenerateBiomedicines Launches Global Phase-3 Studies for GB-0895, an AI-Engineered Antibody Targeting Severe Asthma#USA#Somerville#GenerateBiomedicines#Asthma_Treatment#GB-0895
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895 to Combat Severe Asthma#USA#Somerville#Clinical_Trials#Asthma_Treatment#GB-0895
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895 to Combat Severe Asthma
Generate Biomedicines unveils plans for two global Phase 3 trials assessing GB-0895 treatment for severe asthma, showcasing AI innovation in healthcare.
third-news.com
December 1, 2025 at 11:19 AM
Generate Biomedicines Launches Global Phase 3 Trials for GB-0895 to Combat Severe Asthma#USA#Somerville#Clinical_Trials#Asthma_Treatment#GB-0895
Generate:Biomedicines to Launch Global Phase 3 Studies for AI-Developed Asthma Treatment#Somerville#GenerateBiomedicines#AI_Treatment#GB-0895
Generate:Biomedicines to Launch Global Phase 3 Studies for AI-Developed Asthma Treatment
Generate:Biomedicines announces the initiation of two global Phase 3 studies for GB-0895, a long-acting antibody for severe asthma, developed using AI.
third-news.com
December 1, 2025 at 11:18 AM
Generate:Biomedicines to Launch Global Phase 3 Studies for AI-Developed Asthma Treatment#Somerville#GenerateBiomedicines#AI_Treatment#GB-0895
GenerateBiomedicines Launches Phase 3 Trials for AI-Engineered Antibody Against Severe Asthma#USA#Somerville#GenerateBiomedicines#GB-0895#Severe_Asthma
GenerateBiomedicines Launches Phase 3 Trials for AI-Engineered Antibody Against Severe Asthma
GenerateBiomedicines announces the initiation of global Phase 3 trials for its AI-engineered monoclonal antibody GB-0895, targeting severe asthma treatment.
third-news.com
December 1, 2025 at 11:17 AM
GenerateBiomedicines Launches Phase 3 Trials for AI-Engineered Antibody Against Severe Asthma#USA#Somerville#GenerateBiomedicines#GB-0895#Severe_Asthma
GenerateBiomedicines Kicks Off Global Phase 3 Trials for Innovative Asthma Treatment#USA#Somerville#GenerateBiomedicines#GB-0895#TSLP
GenerateBiomedicines Kicks Off Global Phase 3 Trials for Innovative Asthma Treatment
GenerateBiomedicines is set to begin two massive Phase 3 clinical trials for GB-0895, an advanced anti-TSLP antibody aimed at treating severe asthma effectively.
third-news.com
December 1, 2025 at 11:14 AM
GenerateBiomedicines Kicks Off Global Phase 3 Trials for Innovative Asthma Treatment#USA#Somerville#GenerateBiomedicines#GB-0895#TSLP
Generate Biomedicines to Showcase Groundbreaking Phase 1 Results for AI-Engineered GB-0895 at European Respiratory Society Congress#United_States#Somerville#GenerateBiomedicines#GB-0895#AsthmaTreatment
Generate Biomedicines to Showcase Groundbreaking Phase 1 Results for AI-Engineered GB-0895 at European Respiratory Society Congress
Generate Biomedicines is set to present Phase 1 results of GB-0895, an AI-engineered treatment for asthma, at the European Respiratory Society Congress.
third-news.com
September 25, 2025 at 11:12 AM
Generate Biomedicines to Showcase Groundbreaking Phase 1 Results for AI-Engineered GB-0895 at European Respiratory Society Congress#United_States#Somerville#GenerateBiomedicines#GB-0895#AsthmaTreatment
CSL Behring's VP R&D Transplant & Immunology & GSK alum Laurie Lee was recruited by AI-focused clinical stage biotech Generate Biomedicines as Chief Medical Officer. She'll lead the late stage development of GB's respiratory & dermatology treatments in clinical trials. Incl GB-0895 4 severe asthma
September 17, 2025 at 1:45 PM
CSL Behring's VP R&D Transplant & Immunology & GSK alum Laurie Lee was recruited by AI-focused clinical stage biotech Generate Biomedicines as Chief Medical Officer. She'll lead the late stage development of GB's respiratory & dermatology treatments in clinical trials. Incl GB-0895 4 severe asthma
Check out the putative MOA of Generate Biomedicines's GB-0895, our monoclonal antibody for optimally inhibiting TSLP, a cytokine that drives asthma symptoms like shortness of breath. www.youtube.com/watch?v=KyR4...
GB-0895 (anti-TSLP) Putative MOA Video
YouTube video by Generate:Biomedicines
www.youtube.com
January 13, 2025 at 2:00 PM
Check out the putative MOA of Generate Biomedicines's GB-0895, our monoclonal antibody for optimally inhibiting TSLP, a cytokine that drives asthma symptoms like shortness of breath. www.youtube.com/watch?v=KyR4...